Understand the source comparison
KPV for Crohn's Disease Research: Comparison of Mechanism Classes
Before evaluating KPV's potential, understand how it differs mechanistically from established Crohn's therapies. TNF-α Inhibitors (Biologics) Infliximab, Adalimumab Neutralize circulating TNF-α after production High. Systemic infection risk, reactivation of la
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before evaluating KPV's potential, understand how it differs mechanistically from established Crohn's therapies.
- TNF-α Inhibitors (Biologics)
- Infliximab, Adalimumab
- Neutralize circulating TNF-α after production
- High. Systemic infection risk, reactivation of latent TB
- Low. Systemic distribution
- Gold standard for moderate-to-severe disease but carries infection and malignancy risk with long-term use
- IL-12/IL-23 Inhibitors
- Ustekinumab
- Block p40 subunit shared by IL-12 and IL-23
- Moderate. Selective immune pathway suppression
- Effective in anti-TNF failures but still systemically active. Not mucosal-targeted
- Integrin Inhibitors
- Vedolizumab
- Block α4β7 integrin to prevent lymphocyte gut homing
- Low. Gut-selective mechanism
- High. Targets gut lymphocyte trafficking specifically
- Gut-selective but acts on adaptive immunity, not innate inflammation at epithelial level
- Corticosteroids
- Prednisone, Budesonide
- Broad immune suppression via glucocorticoid receptor
- Very High. Infection, osteoporosis, adrenal suppression
- Variable. Budesonide has some mucosal selectivity
- Effective for flares but unsuitable for maintenance due to side effect burden
- Melanocortin Peptides
- KPV (research-stage)
- Inhibit NF-κB translocation via MC1R signaling
- Minimal. Targets transcription factor, not immune cells
- High. Mucosal retention in inflamed tissue
- Mechanistically distinct from all approved therapies. No systemic immune suppression in preclinical models, but human efficacy data insufficient for regulatory approval